NVS - Novartis: Buy This Blue-Chip Dividend Stock On Sale Now

2024-05-27 07:00:00 ET

Summary

• Novartis is a business that has shown tremendous resiliency, operating for hundreds of years.
• The multinational Swiss pharmaceutical topped the analyst consensus for revenue and core EPS in Q1.
• Novartis' net debt load is minimal, which justifies its prime credit rating from S&P.
• The big pharma company's shares could be trading at an 18% discount to fair value.
• Novartis could be positioned to deliver 35%+ cumulative total returns by the end of 2026.

In this life, the truth is that nothing lasts forever. Milk and eggs have an expiration date. Our lives all expire.

Businesses cease to exist or are rolled up into other businesses. Think Japan's Kongo Gumi construction company, which was founded in 578 AD. In 2006, even it was liquidated. Technically, it still operates today as part of the subsidiary of Takamatsu Construction Group. But it is no longer the standalone company that it was for nearly one and a half millennium....

For further details see: